Interleukin 17A -197 G/A gene polymorphism and interleukin-17 serum level in patients with Spondyloarthropathy

Background: Although the exact cause of spondyloarthropathy (SpA) is unknown, evidence points to the importance of interleukin-mediated immune responses 17A (IL-17A) in the progression of the condition. Objective: is to assess how IL17A gene polymorphism in the -197 G/A promoter region affects IL17 levels, disease severity, and treatment response in spondyloarthropathy patients. Methodology: A total of 65 Egyptians, 35 of them are patients with SpA, have been registered at the Aswan University Clinical Rheumatology department. Thirty healthy volunteers whose ages and sexes are matched to those of the patient group. Demographic information was given to each participant. Clinical examination, as well as a laboratory evaluation that included measuring the level of IL-17A in their serum using ELISA, Additionally, Extracted DNA was used for genotyping. Results: Of our cases, 17 patients (48.57%) were females and 18 were males (51.43%) In our investigation, the serum IL-17A levels of the patients and the controls differed significantly. The patients' levels of IL-17 were significantly higher in SpA than the controls'. The level of IL-17A in SpA was significantly correlated with either its active state (AS or PsA) or its sub-tyes, with a distinct cutoff point. The genotyping results for IL 17A -197 G/A in patients and the control group did not differ significantly.conclusion, our research suggests that IL-17A is a low-cost valued, and practical biomarker for identifying SpA in patients without symptoms and helps in early diagnosis of the disease to prevent development of disabilities.